Form 4: MeiraGTx Director Thomas Shenk Granted 45,000 Restricted Share Units

MeiraGTx Holdings plc Director Thomas E. Shenk was granted 45,000 Restricted Share Units, which will convert into ordinary shares upon settlement and vest by June 2026.

Summary

• Thomas E. Shenk, a Director of MeiraGTx Holdings plc (MGTX), was granted 45,000 Restricted Share Units (RSUs) on June 12, 2025.
• Each Restricted Share Unit converts into one ordinary share of MeiraGTx Holdings plc upon settlement.
• The RSUs are set to vest in a single annual installment upon the earlier of June 12, 2026, or the day immediately prior to the Issuer's annual meeting of shareholders in 2026.
• The reporting person elected to have the restricted share units become settleable when they cease to be a director.
• Following this transaction, Thomas E. Shenk beneficially owns 45,000 derivative securities in the form of Restricted Share Units.

Sentiment

Score: 7

Explanation: The grant of Restricted Share Units to a director is a positive event as it aligns the director's long-term interests with those of the shareholders, representing a standard and beneficial form of equity compensation.

Positives

• The grant of Restricted Share Units to Director Thomas E. Shenk aligns his long-term interests with those of the company's shareholders.
• Equity compensation is a standard practice that incentivizes directors to contribute to the company's sustained growth and performance.

Future Outlook

The grant of Restricted Share Units indicates a future increase in Thomas E. Shenk's direct beneficial ownership of MeiraGTx ordinary shares upon vesting and settlement, aligning his long-term incentives with the company's performance.

Industry Context

The grant of Restricted Share Units to a director is a common and widely accepted practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract, retain, and incentivize key leadership by aligning their financial interests with long-term shareholder value.

Comparison to Industry Standards

• Equity compensation, such as Restricted Share Units, is a standard component of director remuneration across the biotechnology sector, including companies comparable to MeiraGTx Holdings plc.
• The structure of vesting over approximately one year is typical for annual director equity grants, similar to practices observed at companies like Sarepta Therapeutics or BioMarin Pharmaceutical, which often use RSUs to incentivize long-term commitment.

Related Party Transactions

• The grant of Restricted Share Units to Thomas E. Shenk, a Director, constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Director (Thomas E. Shenk): Receives equity compensation, incentivizing continued service and performance.

Next Steps

• The Restricted Share Units are expected to vest in a single annual installment upon the earlier of June 12, 2026, or the day immediately prior to the Issuer's annual meeting of shareholders in 2026.
• Upon vesting and settlement, the Restricted Share Units will convert into ordinary shares of MeiraGTx Holdings plc.

Key Dates

Keywords

MeiraGTx Holdings plc, MGTX, Thomas Shenk, Restricted Share Units, RSU, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant